Clinical Trials | August 04, 2022
Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The WAVEsystem with the WAVEcontrol 4.0 embedded
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
The total budget of Rs. 3119.46 crores has been allocated/ released as a central share to States/UTs since the inception of the scheme and they have reported an expenditure of Rs. 2290.20 crores.
The company has reported total income of Rs. 128.79 crores during the period ended June 30, 2022.
The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.
The two generic drugs have been launched under the brand names Jankey & Sitenali.
he company has reported total income of Rs. 5478.62 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
